The DDI Marker Studies Knowledgebase has been updated in April 2024, and is available in the DIDB Resource Center.
Our Editorial Team had dedicated efforts on identifying inhibitors for BCPP and OATP1B1/1B3 transporters, revealing 22 inhibitors of these transporters among this update. In summary, 42 compounds were identified as substates, inhibitors, and inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3) in this update. Notably, 5 compounds were sensitive substrates, and 1 was a strong inhibitor, potentially leading to significant drug interactions mediated by CYP1A2, CYP2D6, and CYP3A.
For enhanced accessibility, we’ve introduced a “Recent Update” column (Column AE) on the spreadsheet. Simply select “yes” to view a comprehensive list of additions and modifications, including new compounds and updates to existing cells.
In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.
As always, feel free to contact us if you have any questions or comments.